Palleon Pharmaceuticals has reported the outcomes from its Phase I/II study of E-602 along with programmed death (PD)-1 inhibitor cemiplimab (Libtayo ... Phase I/II clinical trial for E-602.

Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings from a phase 2 trial in ... has shown a clinical benefit in ...

Dr Israel Lowy, senior vice president of translational and clinical sciences in ... and vice-chair of the Trial Steering Committee, commented: “Libtayo is an important advancement for patients ...

Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, ...

Regeneron aims to advance cancer treatments through innovative research and partnerships while emphasizing the significance of their PD-1 inhibitor, Libtayo, in ongoing clinical trials.

including Libtayo, which is already a standard of care for advanced CSCC, and linvoseltamab, which has shown promise in clinical trials. The investigational uses of Libtayo, fianlimab, REGN7075 ...

Senhwa Biosciences, Inc., a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced that the completion of Clinical Study ...

FibroGen said it believes that the mechanisms of action for both FG-3165 and FG-3175 have the potential to be synergistic with Libtayo, also known as cemiplimab, which could improve clinical outcomes.

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.